BHCM
BBIO icon

Boulder Hill Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Boulder Hill Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,400
Closed -$133K – 137
2022
Q4 		$133K Buy
+17,400
New +$167K 0.11% 116

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Boulder Hill Capital Management's BBIO Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2023, closing a stake of 17,400 shares — an estimated $133K sold.

Boulder Hill Capital Management first reported a position in BBIO in Q4 2022 and held it in 1 quarter. The position peaked at $133K in Q4 2022. 213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining BridgeBio Pharma position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 17,400 BridgeBio Pharma shares in Q1 2023, an estimated $133K.
  • Boulder Hill Capital Management first reported a position in BridgeBio Pharma in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's BridgeBio Pharma position peaked at $133K in Q4 2022.
  • 213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.